Search | CATIE - Canada's source for HIV and hepatitis C information

Jump to Navigation Jump to Content

Sort Results

Filter by Topic

Treatment (remove)
- HIV drugs (remove)
  - Darunavir (Prezista) (remove)
  - Atazanavir (Reyataz) (2)
  - Dolutegravir (Tivicay) (2)
  - Raltegravir (Isentress, Isentress HD) (2)
  - Biktarvy (1)
  - Doravirine (Pifeltro) (1)
  - Efavirenz (Sustiva) (1)
- Drug treatment strategies (3)

Filter by Infection

HIV (remove)

Filter by Resource Category

Search results

Current filters: HIV, Treatment, HIV drugs, Darunavir (Prezista)

8 search results

Switching to Biktarvy from a protease inhibitor–based regimen: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage
Winnipeg doctors use dolutegravir and darunavir for simplifying treatment: 2018, CATIE
Research summary - Webpage
Doravirine vs. darunavir: From TreatmentUpdate 220
2017, CATIE
Research summary - Webpage
Comparing the tolerability and effectiveness of initial therapy: From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage
Dual therapy with raltegravir and darunavir: From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage
Dolutegravir vs. darunavir for the initial treatment of HIV: From TreatmentUpdate 199
2013, CATIE
Research summary - Webpage
Prezista: 2014, CATIE
Fact sheet
Study finds replacing efavirenz with darunavir improves vitamin D levels: 2010, CATIE
Research summary - Webpage

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.

Please note that some content on this website contains language, information and images related to sexuality and drug use, and may not be intended for people of all ages. CATIE ensures that these resources, developed to help prevent the transmission of HIV, hepatitis C and other infections, are written and reviewed by health experts for content accuracy.